SITC 2023 | Novel immunotherapy decoy-resistant IL-18 for the treatment of renal cell carcinoma

David Schoenfeld, MD, PhD, Yale School of Medicine, New Haven, CT, provides an overview of the decoy-resistant IL-18 protein for renal cell carcinoma treatment. IL-18, a pro-inflammatory cytokine, stimulates T-cells and lymphocytes, making it a potential target for immuno-oncology. However, its efficacy is hindered by the presence of IL-18 binding protein, which inhibits its action. A decoy-resistant IL-18 protein that avoids this inhibition has shown preclinical efficacy, where increased IL-18 binding protein expression in patients with renal cell carcinoma is associated with poorer treatment response and survival. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.